TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9179430
Drug: Placebo nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo nasal spray (for 14 days)
Study: 23730580
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate nasal spray
Study: 8255415
Drug: 5HT group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5HT group (5HT-1a agonist under normal temperature)
Study: 3895827
Drug: 100 ml
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml of cold carbonated water
Study: 3895827
Drug: 100 ml
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml of lukewarm tap water
Study: 3895827
Drug: 25 ml
Normalized name: ethanol 6.025 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 ml of lukewarm tap water
Study: 25382508
Drug: Autoinoculation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autoinoculation therapy
Study: 22584566
Drug: sHT treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: sHT treatment
Study: 20443153
Drug: 80% inspired
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80% inspired oxygen via PULMANEX Hi‐Ox Mask (10 L/min)
Study: 20443153
Drug: 30% oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30% oxygen via nasal cannula (2 L/min)
Study: 18536191
Drug: Fluoxetine (20‐60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (20‐60 mg/day)
Study: 18536191
Drug: Imipramine (50‐150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (50‐150 mg/day)
Study: 12462772
Drug: Propacetamol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propacetamol (2 g intravenous single dose)
Study: 12462772
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of propacetamol and promedol (opioid analgesic)
Study: 7568839
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of digital subtraction and fluoroscopic spot images
Study: 2188773
Drug: pyrazinoylguanidine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: pyrazinoylguanidine (300 mg b.i.d.)
Study: 2188773
Drug: pyrazinoylguanidine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: pyrazinoylguanidine (600 mg b.i.d.)
Study: 2188773
Drug: pyrazinoylguanidine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: pyrazinoylguanidine (300 mg b.i.d. for 3 days)
Study: 2188773
Drug: pyrazinoylguanidine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: pyrazinoylguanidine (600 mg b.i.d. for 3 days)
Study: 6777806
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg diazepam (DZ)
Study: 6777806
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg N-desmethyldiazepam (NDDZ)
Study: 30910531
Drug: Behavioural intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Behavioural intervention plus supplies for syphilis testing and treatment
Study: 21631324
Drug: gp100:209‐217(210M) peptide
Approvals — FDA: no, EMA: no, PMDA: no
Description: gp100:209‐217(210M) peptide vaccine plus interleukin‐2 (720,000 IU per kilogram of body weight per dose)
Study: 21631324
Drug: Interleukin‐2 alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interleukin‐2 alone (720,000 IU per kilogram of body weight per dose)
Study: 21631324
Drug: gp100:209‐217(210M) peptide
Approvals — FDA: no, EMA: no, PMDA: no
Description: gp100:209‐217(210M) peptide vaccine plus interleukin‐2
Study: 12477759
Drug: Substance P
Normalized name: Substance P
DrugBank: Substance P (DB19198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Substance P (highest dose)
Study: 12477759
Drug: Neurokinin A
Normalized name: Neurokinin p
DrugBank: Substance P (DB19198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurokinin A (highest dose)
Study: 8858463
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg ILd‐AmB (group A)
Study: 8858463
Drug: 1.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg/kg ILd‐AmB (group B)
Study: 6733006
Drug: Propranolol L.A.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol L.A. (160 mg)
Study: 22628490
Drug: Oral treprostinil
Normalized name: Treprostinil
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral treprostinil (1.25 to 3.25 mg)
Study: 22628490
Drug: Oral treprostinil
Normalized name: Treprostinil
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral treprostinil (3.5 to 16 mg)
Study: 19028384
Drug: Clomiphene (CC)
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene (CC)
Study: 15653083
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment (1-year exercise program)
Study: 12165396
Drug: D-penicillamine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-penicillamine treatment for 24 weeks
Study: 10036338
Drug: 75 g
Normalized name: Zosyn 3.375 GM Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 g liquid carbohydrate with 14.5 g encapsulated guar gum (FIB)
Study: 10036338
Drug: 75 g
Normalized name: Zosyn 3.375 GM Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 g liquid carbohydrate (GLU)
Study: 2085083
Drug: Atracurium administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium administered by a priming technique (0.1 mg/kg i.v. followed by 0.5 mg/kg after 6 min)
Study: 2085083
Drug: Atracurium bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium bolus injection (0.6 mg/kg)
Study: 17721249
Drug: 0.2% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% ropivacaine (10-ml bolus followed by an infusion of 10 ml/h during 48 h)
Study: 15090815
Drug: Nevirapine 200
Normalized name: nevirapine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nevirapine 200 mg twice a day
Study: 9778665
Drug: Ketamine (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (target plasma concentrations of 50, 100, 150, and 200 ng/ml)
Study: 2201729
Drug: Zopiclone (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zopiclone (5 or 7.5 mg)
Study: 2201729
Drug: Triazolam (0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam (0.125 or 0.25 mg)
Study: 414196
Drug: Inhaled cromolyn
Normalized name: cromolyn Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled cromolyn sodium (Intal)
Study: 414196
Drug: Oral theophylline
Normalized name: theophylline Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral theophylline (Slo-Phyllin tablets, 7.5 mg/kg)
Study: 30715250
Drug: C-reactive protein
Normalized name: C-reactive protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: C-reactive protein (CRP)-informed strategy (CRP ≥80 mg/L plus age/temperature-corrected tachypnea and/or chest indrawing)
Study: 22542612
Drug: GA combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: GA combined with pre‐emptive nerve stimulator‐guided pudendal nerve block (PNB) with 10 mL of 0.25% bupivacaine on each side
Study: 1691287
Drug: Isoprinosine 4
Normalized name: Isoprénaline
DrugBank: Isoprenaline (DB01064)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoprinosine 4 g/day (1 g q.i.d.) + Ribavirin 800 mg/day
Study: 1691287
Drug: Isoprinosine 4
Normalized name: Isoprénaline
DrugBank: Isoprenaline (DB01064)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoprinosine 4 g/day (1 g q.i.d.) + Ribavirin 1200 mg/day
Study: 1691287
Drug: Treatment (Ribavirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment (Ribavirin and Isoprinosine)
Study: 6779148
Drug: Persantine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Persantine plus Aspirin (PR/A)
Study: 20739720
Drug: Taurine (1.66
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taurine (1.66 g)
Study: 17654298
Drug: Telephone booster
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone booster sessions after intensive inpatient treatment
Study: 15941534
Drug: Multiple micronutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple micronutrients supplementation (vitamin A 600 microg, beta-carotene 1.0 mg, vitamin E 100 mg, vitamin C 300 mg, Na2SeO3 200 microg daily for 8 weeks)
Study: 12044624
Drug: Regular opioids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular opioids plus low dose intravenous ketamine (0.6 mg/kg)
Study: 10442368
Drug: Weekly paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly paclitaxel by 1-hour infusion plus UFT/oral calcium folinate
Study: 2349134
Drug: Diltiazem 60
Normalized name: DILTIAZEM 60MG 12HR CAP,SA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 60 mg orally four times a day for 1 week
Study: 2349134
Drug: Propranolol 40
Normalized name: propranolol 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 40 mg orally four times a day for 1 week
Study: 367411
Drug: Caffeine 75
Normalized name: caffeine 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 75 to 300 mg
Study: 367411
Drug: Cyclizine 25
Normalized name: cyclizine 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclizine 25 mg
Study: 367411
Drug: Caffeine 100
Normalized name: caffeine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 100 mg + Cyclizine 50 mg
Study: 367411
Drug: Caffeine 100
Normalized name: caffeine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 100 mg + Cyclizine 100 mg
Study: 28072706
Drug: GemCap (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: GemCap (oral capecitabine 1660 mg/m plus Gem 1000 mg/m by 30‐minute intravenous infusion weekly for 3 weeks followed by a 1‐week break every 4 weeks)
Study: 28072706
Drug: Gem (by
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gem (by 30‐minute intravenous infusion weekly for 3 weeks every 4 weeks)
Study: 26468172
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injection (1mL triamcinolone acetonide 10mg/mL and 1mL lidocaine 2%)
Study: 23104564
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (vitamin D 600,000 IU single intramuscular dose + calcium 75 mg/kg/day elemental calcium orally)
Study: 23104564
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D alone (600,000 IU single intramuscular dose)
Study: 23104564
Drug: Calcium alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium alone (75 mg/kg/day elemental calcium orally)
Study: 21503388
Drug: Clinical treatment
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical treatment
Study: 8894432
Drug: Oxiconazole nitrate
Normalized name: Oxiconazole Nitrate
DrugBank: Oxiconazole (DB00239)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxiconazole nitrate cream, 1 percent (monotherapy)
Study: 8894432
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with oxiconazole nitrate cream, 1 percent and fluticasone propionate cream, 0.05 percent
Study: 6349785
Drug: BCNU (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCNU (80 mg/m2/day IV X 3 and repeat every 8 weeks)
Study: 6349785
Drug: methyl‐CCNU (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: methyl‐CCNU (125 mg/m2/day orally X 1 and repeat every 8 weeks) + DTIC (150 mg/m2/day IV X 5 and repeat every 4 weeks)
Study: 6349785
Drug: Higher radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Higher radiation dose (7000 rad/8-9 weeks)
Study: 28360825
Drug: Oxygen supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen supplement (OS)
Study: 21807562
Drug: Endoscopic injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic injection
Study: 19567163
Drug: Homoharringtonine (HHT)
Normalized name: HHT
DrugBank: Omacetaxine mepesuccinate (DB04865)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Homoharringtonine (HHT) 1.5 mg/m² by continuous daily infusion for seven to nine days every four weeks
Study: 19567163
Drug: HHT as
Normalized name: HHT
DrugBank: Omacetaxine mepesuccinate (DB04865)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HHT as salvage treatment for patients who failed IFN‐alpha
Study: 17012656
Drug: Standardised outcome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardised outcome assessment (monthly postal questionnaires and 3-monthly feedback)
Study: 15007003
Drug: Warfarin use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin use
Study: 9507837
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg phentolamine
Study: 9507837
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg phentolamine
Study: 9507837
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg phentolamine
Study: 8042808
Drug: Mivacurium chloride
Normalized name: Mivacurium Chloride
DrugBank: Mivacurium (DB01226)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mivacurium chloride (0.15 mg.kg‐1)
Study: 3055819
Drug: Percutaneous estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Percutaneous estradiol gel
Study: 23358639
Drug: Protease inhibitor
Normalized name: Protease inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protease inhibitor (PI)-based antiretroviral therapy (ART)
Study: 23358639
Drug: Non-nucleoside reverse
Normalized name: Non-nucleoside reverse transcriptase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-nucleoside reverse transcriptase inhibitor-based ART
Study: 7584704
Drug: Oral ethinyl
Normalized name: ethinyl estradiol Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ethinyl estradiol at a dose of 100 ng/kg/day
Study: 7584704
Drug: Transdermal 17
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal 17 beta‐estradiol via adhesive skin patch at 0.0125 mg/kg/day
Study: 1980660
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg metoprolol (long-acting)
Study: 1980660
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg metoprolol + 120 mg ISDN (sustained-release)
Study: 1980660
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg metoprolol + 120 mg diltiazem (sustained-release)
Study: 1980660
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg metoprolol + 10 mg nisoldipine
Study: 1980660
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg metoprolol + 120 mg ISDN + 120 mg diltiazem
Study: 1980660
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg metoprolol + 120 mg ISDN + 10 mg nisoldipine
Study: 6841564
Drug: Diazepam (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (3 days treatment)
Study: 30085178
Drug: High-dose SP
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose SP strain vaccine
Study: 30085178
Drug: Low-dose SP
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose SP strain vaccine
Study: 30085178
Drug: High-dose S79
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose S79 vaccine
Study: 30085178
Drug: Low-dose S79
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose S79 vaccine
Study: 27935886
Drug: Detralex (micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detralex (micronized purified flavonoid fraction) at a daily dose of 1,000 mg for 2 weeks prior to sclerotherapy and for at least 2 months after the procedure
Study: 27935886
Drug: Control Group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control Group (no drug)
Study: 22782376
Drug: High-energy extracorporeal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-energy extracorporeal shock wave therapy (ESWT)
Study: 21048483
Drug: TimeSlips intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TimeSlips intervention (twice-weekly for 6 weeks)
Study: 17237006
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (CT) or chemoradiation (CRT) followed by surgery for stage IIb
Study: 15708211
Drug: Sentences with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sentences with semantically complex verbs (e.g., causatives)
Study: 7751684
Drug: Intranasal bovine
Normalized name: Pegademase Bovine
DrugBank: Pegademase (DB00061)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal bovine parainfluenza virus type 3 (BPIV‐3) vaccine
Study: 1968773
Drug: Adrenergic agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenergic agonists (Clonidine and Guanfacine)
Study: 31143445
Drug: Lipid-based nutrient
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-based nutrient supplements with added high-dose vitamins and minerals (LNS-VM)
Study: 29735881
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream plus Vapocoolant spray
Study: 29735881
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream only
Study: 20678684
Drug: Midazolam 7.5
Normalized name: midazolam 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 7.5 mg alone (treatment A)
Study: 20678684
Drug: Midazolam 7.5
Normalized name: midazolam 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 7.5 mg with zibotentan 10 mg once daily (treatment B)
Study: 23381694
Drug: Zibotentan 10
Normalized name: Zibotentan
DrugBank: Zibotentan (DB06629)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zibotentan 10 mg once daily
Study: 15711832
Drug: Triflusal 900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triflusal 900 mg single oral dose
Study: 15711832
Drug: Triflusal 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triflusal 600 mg once daily for 14 days
Study: 14728939
Drug: Rectal bleeding
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal bleeding
Study: 6986236
Drug: Clocortolone pivalate
Normalized name: Clocortolone Pivalate
DrugBank: Clocortolone (DB00838)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clocortolone pivalate 0.1 percent cream
Study: 348406
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream base
Study: 17488660
Drug: C.E.R.A. 1.0-4.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: C.E.R.A. 1.0-4.2 mg/kg
Study: 17488660
Drug: C.E.R.A. 2.0-8.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: C.E.R.A. 2.0-8.0 mg/kg
Study: 15015070
Drug: IVCP (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVCP (500 mg/m² per month IV for 6 months)
Study: 15015070
Drug: OCP (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: OCP (2 mg/kg per day for 12 weeks)
Study: 11235791
Drug: Seat properties
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seat properties (geometry, stiffness, energy absorption)
Study: 3289737
Drug: 1 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/m2 monoclonal anti-carcinoembryonic antigen (CEA) antibody, NP-2, administered three times weekly or once a week for 12 to 240 days (5 to 13 injections)
Study: 20601412
Drug: Transdermal testosterone
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal testosterone (50 mg) daily for 6 months
Study: 20601412
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel daily for 6 months
Study: 18694901
Drug: Sublingual buprenorphine
Normalized name: buprenorphine Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual buprenorphine (13.2 to 39.0 mug/kg per day in 3 divided doses)
Study: 18694901
Drug: Standard-of-care oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care oral neonatal opium solution
Study: 12612897
Drug: NCX-4016 (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: NCX-4016 (400 and 800 mg twice daily)
Study: 12612897
Drug: Aspirin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (200 and 420 mg twice daily)
Study: 10234582
Drug: Alendronate (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (10 mg/day) and calcium carbonate (500 mg/day)
Study: 3826200
Drug: Clonidine transdermal
Normalized name: Clonidine Transdermal System
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine transdermal therapeutic system
Study: 30460981
Drug: Low-dose intravenous
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose intravenous haloperidol (0.5 mg three times daily for a total of 11 doses)
Study: 30460981
Drug: Low-dose intravenous
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose intravenous haloperidol (0.5 mg three times daily for a total of 11 doses) in esophagectomy subgroup
Study: 19341446
Drug: 3 microg
Normalized name: Calcitriol 3 microgram/g cutaneous ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 microg intradermal vaccine
Study: 19341446
Drug: 6 microg
Normalized name: Zotarolimus 1.6 microgram/mm2 drug eluting stent
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 microg intradermal vaccine
Study: 19341446
Drug: 9 microg
Normalized name: Hyoscine 13.889 microgram/hour prolonged-release transdermal patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 microg intradermal vaccine
Study: 19341446
Drug: 15 microg
Normalized name: Tafluprost 15 microgram/mL eye drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 microg intramuscular vaccine
Study: 19341446
Drug: Intramuscular and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular and intradermal vaccinations
Study: 12969534
Drug: Accelerated fractionated
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated fractionated radiotherapy (AF group, n=138, 6 fractions per week, 180‐190 cGy per day, total dose 7,400‐7,600 cGy)